Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Days Payable Outstanding (DPO) 3 year CAGR for the quarter ending January 31, 2024: 294.03%

Kalvista Pharmaceuticals Inc Days Payable Outstanding (DPO) 3 year CAGR is 294.03% for the quarter ending January 31, 2024, a 83.98% change year over year. The days payables outstanding ratio measures the average number of days it takes for a company to pay its suppliers. It is calculated by dividing accounts payable by the cost of revenue and then multiplying by 365. This ratio indicates the average payment period for suppliers and reflects the efficiency of managing trade payables. A longer period suggests extended payment terms and potential working capital advantages. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Kalvista Pharmaceuticals Inc Days Payable Outstanding (DPO) for the quarter ending January 31, 2023 was 2,965.41.
Kalvista Pharmaceuticals Inc Days Payable Outstanding (DPO) for the quarter ending January 31, 2020 was 95.89, a -32.96% change year over year.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends